查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401931

2030 年干粉吸入器市场预测：按产品、功能、适应症、最终用户和地区进行的全球分析

Dry Powder Inhalers Market Forecasts to 2030 - Global Analysis By Product (Multi Dose Dry Powder Inhalers and Single Dose Dry Powder Inhalers), Function, Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球干粉吸入器市场规模为 214.8 亿美元，预计预测期内复合年增长率为 6.6%，到 ​​2030 年将达到 336 亿美元。

干粉吸入器是一种将粉末状药物直接吸入肺部的医疗设备。它经常被用来治疗肺部相关和呼吸系统疾病，例如气喘和慢性阻塞性肺病（COPD）。与定量喷雾吸入器(MDI) 相比，它们不需要推进剂来输送药物，也不需要手部呼吸协调，这使得它们适合那些难以使用 MDI 的人。我就是。

根据2020年4月发表的一篇题为《常见呼吸系统疾病》的论文，约15%的老年人患有气喘、慢性阻塞性肺病或其他呼吸系统疾病。

呼吸道疾病盛行率上升

囊肿纤维化、气喘和慢性阻塞性肺病(COPD) 等呼吸系统疾病的盛行率不断增加，直接推动了对有效吸入疗法的需求。干粉吸入器作为治疗这些疾病的一种手段有着很高的需求，因为它们提供了一种将药物直接输送到肺部的实用且有效的方法。随着患有呼吸道疾病的人数不断增加，越来越重视症状管理、避免病情加重和加强整体疾病控制对于维持长期症状控制和即时缓解症状非常重要。干粉吸入器越来越多地被使用，发挥着关键作用。对市场成长的推动作用。

製造成本高、应用困难

由于疾病管理困难而导致的药物不依从性可能会导致治疗不足、疾病恶化和医疗费用增加。如果患者发现难以操作或装载干粉吸入器，他们可以选择使用替代吸入器，例如雾化器或定量吸入器（MDI）。这些偏好的变化可能会影响干粉吸入器的市场占有率和销售。医疗保健提供者可能需要投入额外的时间和资源来教导患者正确的处理和装载技术。这种额外的培训需求可能会增加病患教育计画的复杂性，进而可能增加医疗成本并阻碍市场成长。

日益关注预防医学和疾病管理

随着医疗保健系统和提供者越来越关注预防性护理，我们鼓励他们关注早期疗育策略。我们透过提供预防性药物治疗来控制症状和阻止病情恶化，为呼吸系统疾病的治疗做出了重大贡献。随着重点转向疾病预防和管理，以病人为中心的照护模式变得越来越重要。干粉吸入器是这些护理模式的补充，使患者能够主动管理呼吸系统疾病，因为它们易于使用且适合自我给药。

由于竞争激烈，原料的可得性

对干粉吸入器等药物治疗方案的依从性差可能导致慢性阻塞性肺病和气喘等呼吸系统疾病的治疗不充分。肺功能下降、病情加重频率增加、症状恶化、住院风险增加都可能是由于给药不完整或不规则造成的。此外，如果患者因各种原因（例如吸入困难）不遵守规定，患者的偏好要求和处方率都会受到影响。因此，它的市场占有率可能比其他类型的吸入器要小。

COVID-19 的影响

疫情期间，随着 COVID-19 提高了人们对呼吸系统健康的认识和对肺部健康的担忧，对包括 DPI 在内的呼吸系统药物的需求激增。患有长期呼吸道疾病的患者寻求获得所需的药物并继续他们的治疗计划。由于行动不便和前往医疗机构就诊的限制，出现了在家中自行用药的趋势。 DPI 可以自我给药且易于使用，使其成为治疗难以定期去医院就诊的呼吸系统疾病的理想选择。

高剂量干粉吸入器细分市场预计将在预测期内成为最大的细分市场

多剂量干粉吸入器领域预计将出现良好的增长，因为它用于将粉状药物直接给药肺部。他们通常使用一个储存器来容纳多剂量的粉末药物，允许患者随着时间的推移服用多次剂量。该设备可以预先安装多种给药，为患者给药弹性，并允许他们按照预定的时间间隔服用建议的剂量。为了满足患者需求并改善治疗效果，该细分市场的製造商不断创新并专注于改进给药系统、设备人体工学和给药精度。

数位吸入器设备预计在预测期内复合年增长率最高。

预计数位操作吸入器设备领域在预测期内将出现最高的复合年增长率。这些吸入器中的数位技术可以改善资料追踪、连接性和患者更好地医嘱遵从性处方时间表等功能。因此，在吸入器设备中添加数位组件的目的是增强对慢性阻塞性肺病（COPD）和气喘等呼吸系统疾病的治疗。数位化操作的吸入器可以支援个人化医疗方法，因为它们可以收集个别患者对治疗的反应和吸入器使用模式的资料，从而推动市场成长。

占有率最大的地区

由于旨在加强呼吸系统健康和疾病管理的众多政府计划和医疗保健法规，预计亚太地区将在预测期内占据最大的市场占有率。支持政策经常鼓励采用 DPI 和其他有效的吸入疗法。透过 DPI 和数位技术（例如提供给药追踪、提醒和连接等功能的智慧吸入器）的结合，可以改善患者的医嘱遵从性和管理。这种以患者为中心的方法正在推动市场的发展。

复合年增长率最高的地区：

气喘和慢性阻塞性肺病等呼吸系统疾病的盛行率不断增加，增加了对有效吸入治疗的需求。 DPI 为治疗这些疾病提供了一种实用且有效的药物给药方式。此外，由于药物输送系统、配方和 DPI 设计的不断创新，市场正在不断成长。为了提高药物医嘱遵从性和有效性，製造商不断致力于开发可携式、易于使用且高效的 DPI。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球干粉吸入器市场：副产品

  • 多剂量干粉吸入器
  • 单给药干粉吸入器

第六章全球干粉吸入器市场：依功能分类

  • 手动吸入器
  • 数位操作吸入器

第七章全球干粉吸入器市场：依适应症分类

  • 肺动脉高血压
  • 慢性阻塞性肺病（COPD）
  • 气喘
  • 囊肿纤维化

第八章全球干粉吸入器市场：依最终用户分类

  • 药局
  • 零售药房
  • 医院
  • 线上药房
  • 门诊手术中心
  • 其他最终用户

第九章全球干粉吸入器市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • GlaxoSmithKline Plc
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • Chiesi Farmaceutici SpA
  • AptarGroup, Inc.
  • Iconovo AB
  • Mylan NV
  • Pharmaxis
  • Teva Pharmaceutical Industries Limited
  • AstraZeneca Plc
  • Novartis AG
  • Elpen SA
  • Vectura Group Plc
  • Beximco Pharmaceuticals Ltd
  • Hovione
  • MannKind Corporation
  • Sava Healthcare Ltd
  • 3M Company
  • DPI Co., Ltd.
Product Code: SMRC24451

According to Stratistics MRC, the Global Dry Powder Inhalers Market is accounted for $21.48 billion in 2023 and is expected to reach $33.60 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dry powder inhalers are medical devices that inhale powdered medication directly into the lungs. For the treatment of lung-related disorders and respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), they are frequently prescribed. They don't need propellants to deliver the medication, in contrast to metered-dose inhalers (MDIs) and are also appropriate for people who might have trouble using MDIs because they do not require hand-breath coordination.

According to the article titled "Common Respiratory Disorders" published in April 2020 around 15% of older adults from asthma, chronic obstructive pulmonary disease, or another respiratory disorder.

Market Dynamics:

Driver:

Rising prevalence of respiratory disorders

The increasing prevalence of respiratory ailments such as cystic fibrosis, bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) directly drives the need for efficient inhalation therapies. Since dry powder inhalers provide a practical and effective means of delivering medication directly to the lungs, they are in high demand as a treatment modality for these conditions. The increasing number of people suffering from respiratory disorders has led to a greater focus on symptom management, averting exacerbations, and enhancing overall disease management and these are used more frequently because of their critical role in sustaining long-term symptom control and offering immediate relief which drives the growth of the market.

Restraint:

High production costs and difficulty in application

Medication noncompliance brought on by difficulties managing the condition may lead to insufficient therapy, worsening of the illness, and higher medical expenses. If patients find Dry powder inhalers difficult to handle or load, they may choose to use alternative inhaler devices like nebulizers or metered-dose inhalers (MDIs). The market share and sales of dry powder inhalers may be impacted by this change in preferences. It may be necessary for healthcare providers to devote additional time and resources to instructing patients on proper handling and loading techniques. The complexity of patient education programs may increase due to this additional training requirement, which may also raise healthcare costs thus hamper the growth of the market.

Opportunity:

Increased focus on preventive care and disease management

Healthcare systems and providers are encouraged to concentrate on early intervention strategies due to the increased emphasis on preventive care. By offering prophylactic medication to manage symptoms and stop exacerbations and they contribute significantly to the management of respiratory conditions. Patient-centric care models are becoming more and more important as the focus shifts to illness prevention and management. Dry powder inhalers complement these care models by empowering patients to actively manage their respiratory conditions because they are easy to use and appropriate for self-administration.

Threat:

Availability of raw materials with intense competition

Insufficient compliance with drug regimens, such as dry powder inhalers, may result in insufficient treatment of respiratory disorders like COPD or asthma. Reduced lung function, an increase in the frequency of exacerbations, worsening symptoms, and an increased risk of hospitalization can all be caused by incomplete or irregular dosing. Moreover, demand of patient preferences, and prescription rates may all be impacted if patients fail to comply for a variety of reasons, such as inhaler difficulties. This might result in having a smaller market share than other kinds of inhalers.

COVID-19 Impact

Demand for respiratory medications, including those given through DPIs, surged during the pandemic as a result of increased awareness of respiratory health and worries about lung health brought on by COVID-19. Patients with long-term respiratory disorders tried to get access to the drugs they needed and continue their treatment plans. There was a move toward at-home medication self-administration due to limitations on mobility and visits to medical facilities. Due to their self-administration capabilities and ease of use, DPIs have become the go-to choice for treating respiratory disorders when regular clinic visits are not feasible.

The multi dose dry powder inhalers segment is expected to be the largest during the forecast period

The multi dose dry powder inhalers segment is estimated to have a lucrative growth, as they are used to administer powdered medication directly into the lungs. They usually use a reservoir that holds multiple doses of the powdered medication, allowing patients to take multiple doses over time. They enable the device to be preloaded with multiple doses, giving patients dosage flexibility and the ability to take their recommended doses at predetermined intervals. In order to meet patient needs and enhance treatment outcomes, manufacturers in this market sector are constantly innovating, concentrating on bettering drug delivery systems, ergonomics of devices, and dose accuracy.

The digitally operated inhaler devices segment is expected to have the highest CAGR during the forecast period

The digitally operated inhaler devices segment is anticipated to witness the highest CAGR growth during the forecast period, because digitally operated inhaler devices are a new and creative segment. Digital technology in these inhalers enables improved features like data tracking, connectivity, and better patient adherence to prescription schedules. Thus, the goal of adding digital components to inhaler devices is to enhance the way respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are managed. Because digitally operated inhalers collect data on individual patient responses to treatment and inhaler usage patterns, they can support personalized medicine approaches thus boosting the growth of the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the as a result of numerous government programs and healthcare regulations targeted at enhancing respiratory health and illness management. Adoption of DPIs and other effective inhalation therapies is frequently encouraged by supportive policies. Patient adherence and management are improved by the combination of DPIs with digital technologies, such as smart inhalers that provide features like dose tracking, reminders, and connectivity. The evolution of the market is driven by this patient-centric approach.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the incidence of respiratory conditions such as asthma and COPD has been increasing, which has increased the need for efficient inhalation treatments. DPIs provide a practical and effective means of administering medicine to treat these ailments. Moreover, the market has grown as a result of ongoing innovations in drug delivery systems, formulations, and DPI designs. To increase medication adherence and efficacy, manufacturers are always working to create DPIs that are more portable, user-friendly, and efficient.

Key players in the market:

Some of the key players profiled in the Dry Powder Inhalers Market include GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A, AptarGroup, Inc., Iconovo AB, Mylan N.V, Pharmaxis, Teva Pharmaceutical Industries Limited, AstraZeneca Plc, Novartis AG, Elpen S.A, Vectura Group Plc, Beximco Pharmaceuticals Ltd, Hovione, MannKind Corporation, Sava Healthcare Ltd, 3M Company and DPI Co., Ltd.

Key Developments:

In October 2023, GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen. There is high unmet need in CHB with an estimated 300 million people living with the disease and a less than 3-7% functional cure rate with current treatment options.

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. New research reveals a nationwide focus on STEM mentoring of under-represented groups could boost individual incomes.

In October 2023, Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs

Products Covered:

  • Multi Dose Dry Powder Inhalers
  • Single Dose Dry Powder Inhalers

Functions Covered:

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

Indications Covered:

  • Pulmonary Arterial Hypertension
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Cystic Fibrosis

End Users Covered:

  • Drug Stores
  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dry Powder Inhalers Market, By Product

  • 5.1 Introduction
  • 5.2 Multi Dose Dry Powder Inhalers
  • 5.3 Single Dose Dry Powder Inhalers

6 Global Dry Powder Inhalers Market, By Function

  • 6.1 Introduction
  • 6.2 Manually Operated Inhaler Devices
  • 6.3 Digitally Operated Inhaler Devices

7 Global Dry Powder Inhalers Market, By Indication

  • 7.1 Introduction
  • 7.2 Pulmonary Arterial Hypertension
  • 7.3 Chronic Obstructive Pulmonary Disease (COPD)
  • 7.4 Asthma
  • 7.5 Cystic Fibrosis

8 Global Dry Powder Inhalers Market, By End User

  • 8.1 Introduction
  • 8.2 Drug Stores
  • 8.3 Retail Pharmacies
  • 8.4 Hospitals
  • 8.5 Online Pharmacies
  • 8.6 Ambulatory Surgical Centers
  • 8.7 Other End Users

9 Global Dry Powder Inhalers Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GlaxoSmithKline Plc
  • 11.2 Boehringer Ingelheim GmbH
  • 11.3 Cipla Limited
  • 11.4 Chiesi Farmaceutici S.p.A
  • 11.5 AptarGroup, Inc.
  • 11.6 Iconovo AB
  • 11.7 Mylan N.V
  • 11.8 Pharmaxis
  • 11.9 Teva Pharmaceutical Industries Limited
  • 11.10 AstraZeneca Plc
  • 11.11 Novartis AG
  • 11.12 Elpen S.A
  • 11.13 Vectura Group Plc
  • 11.14 Beximco Pharmaceuticals Ltd
  • 11.15 Hovione
  • 11.16 MannKind Corporation
  • 11.17 Sava Healthcare Ltd
  • 11.18 3M Company
  • 11.19 DPI Co., Ltd.

List of Tables

  • Table 1 Global Dry Powder Inhalers Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 4 Global Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 5 Global Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 6 Global Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 7 Global Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 8 Global Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 9 Global Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 10 Global Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 11 Global Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 12 Global Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 13 Global Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 14 Global Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 15 Global Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 17 Global Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 18 Global Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 19 Global Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 23 North America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 24 North America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 25 North America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 26 North America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 27 North America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 28 North America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 29 North America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 30 North America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 31 North America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 32 North America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 North America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 34 North America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 35 North America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 36 North America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 North America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 38 North America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 42 Europe Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 43 Europe Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 44 Europe Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 45 Europe Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 46 Europe Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 47 Europe Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 48 Europe Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 49 Europe Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 50 Europe Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 51 Europe Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 52 Europe Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 53 Europe Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 54 Europe Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 55 Europe Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 57 Europe Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 61 Asia Pacific Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 62 Asia Pacific Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 63 Asia Pacific Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 64 Asia Pacific Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 65 Asia Pacific Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 66 Asia Pacific Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 67 Asia Pacific Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 68 Asia Pacific Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 69 Asia Pacific Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 70 Asia Pacific Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 71 Asia Pacific Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 72 Asia Pacific Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 73 Asia Pacific Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 74 Asia Pacific Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 76 Asia Pacific Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 80 South America Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 81 South America Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 82 South America Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 83 South America Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 84 South America Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 85 South America Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 86 South America Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 87 South America Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 88 South America Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 89 South America Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 South America Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 91 South America Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 92 South America Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 93 South America Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 94 South America Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 95 South America Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Dry Powder Inhalers Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Dry Powder Inhalers Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Dry Powder Inhalers Market Outlook, By Multi Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 99 Middle East & Africa Dry Powder Inhalers Market Outlook, By Single Dose Dry Powder Inhalers (2021-2030) ($MN)
  • Table 100 Middle East & Africa Dry Powder Inhalers Market Outlook, By Function (2021-2030) ($MN)
  • Table 101 Middle East & Africa Dry Powder Inhalers Market Outlook, By Manually Operated Inhaler Devices (2021-2030) ($MN)
  • Table 102 Middle East & Africa Dry Powder Inhalers Market Outlook, By Digitally Operated Inhaler Devices (2021-2030) ($MN)
  • Table 103 Middle East & Africa Dry Powder Inhalers Market Outlook, By Indication (2021-2030) ($MN)
  • Table 104 Middle East & Africa Dry Powder Inhalers Market Outlook, By Pulmonary Arterial Hypertension (2021-2030) ($MN)
  • Table 105 Middle East & Africa Dry Powder Inhalers Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) (2021-2030) ($MN)
  • Table 106 Middle East & Africa Dry Powder Inhalers Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 107 Middle East & Africa Dry Powder Inhalers Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 108 Middle East & Africa Dry Powder Inhalers Market Outlook, By End User (2021-2030) ($MN)
  • Table 109 Middle East & Africa Dry Powder Inhalers Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 110 Middle East & Africa Dry Powder Inhalers Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 111 Middle East & Africa Dry Powder Inhalers Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 112 Middle East & Africa Dry Powder Inhalers Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Dry Powder Inhalers Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 114 Middle East & Africa Dry Powder Inhalers Market Outlook, By Other End Users (2021-2030) ($MN)